Cite
MLA Citation
Ulrich Lücking et al.. “Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.” ChemMedChem, vol. 12, 2017, pp. 1776–1793. http://access.bl.uk/ark:/81055/vdc_100053923533.0x000017